Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.
about
An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9Tyrosine kinase inhibitors: from rational design to clinical trials.Transcription factor BACH2 is transcriptionally regulated by the BCR/ABL oncogene.Coordinate regulation of stem cell competition by Slit-Robo and JAK-STAT signaling in the Drosophila testis.Combination therapy with imatinib mesylate (STI571): synopsis of in vitro studies.From Hen House to Bedside: Tracing Hanafusa's Legacy from Avian Leukemia Viruses to SRC to ABL and BeyondInhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia.Tyrosine kinases as targets in cancer therapy - successes and failures.Imatinib mesylate in the treatment of chronic myeloid leukaemia.STI571 as a targeted therapy for CML.Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias.Synergistic antiproliferative effect of imatinib and adriamycin in platelet-derived growth factor receptor-expressing osteosarcoma cells.Effect of tyrosine kinase inhibition using imatinib on normal lymphohematopoietic cells.Morphologic Changes in the Bone Marrow in Patients of Chronic Myeloid Leukemia (CML) Treated with ImatinibMesylate.FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.Breast cancer resistance protein in pharmacokinetics and drug-drug interactions.Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib.Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).Tyrosine kinase inhibitors in pediatric malignancies.Kinase packing defects as drug targets.Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications.Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study.A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes.Imatinib mesylate for the treatment of chronic myeloid leukemia.Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cellsMyeloid Cell Origins, Differentiation, and Clinical Implications.Dasatinib in chronic myeloid leukemia: a review.FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism.A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation.Suboptimal responses in chronic myeloid leukemia: milestones and mechanisms.Evolution of therapies for chronic myelogenous leukemia.How I treat newly diagnosed chronic myeloid leukemia in 2015.Chronic myeloid leukemia: Second-line drugs of choice.Design, Synthesis, and Evaluation of Dasatinib-Amino Acid and Dasatinib-Fatty Acid Conjugates as Protein Tyrosine Kinase Inhibitors.The development of high-content screening (HCS) technology and its importance to drug discovery.Management of pregnant chronic myeloid leukemia patients.Emerging Role of Tyrosine Kinases as Drugable Targets in Cancer.
P2860
Q33308713-8A0AF38C-D828-447C-97E9-B3DDC45397D3Q34016866-DEBD400C-0C91-4B29-9548-D8DCE508009FQ34064832-96CBFFB0-4C74-4891-A199-FAEFE7686133Q34095776-3722D292-08E9-487C-B547-7E3A4DC604E1Q34105380-69E4B5C7-DD82-463C-8C4B-F24826632586Q34464595-C1AC2E28-51CD-4F96-A1CE-7C486D01AF33Q34929081-B549804B-87E8-450B-8435-8BA1BDCD0132Q34972855-A31FDBF1-B3C0-4E23-98A7-D9A23CCD416BQ35022505-93F05FA9-2EEF-4D35-92F1-9031AAF68E09Q35022511-0C33248E-246A-44D2-8602-282B367A25B0Q35095147-73084152-E30F-4BA2-A7F6-1EF1651AC912Q35143966-5A6AE6D9-2831-4430-808E-A8A9AA8C9367Q35193288-F4E7FE56-B7F5-43C1-AE9D-0BD34D4D7C95Q35567255-B4A5C978-6AD1-413E-B39C-034AF02758B2Q35904214-F401A643-E39F-4543-8EB4-8689EEBBC95AQ36164524-A1CCFC94-4490-4B5F-906C-F59C8538E40BQ36173719-B4176F23-087C-4384-970A-91DB06081141Q36334327-0E1D2A9B-980D-47DF-8CD3-E83F73A190A0Q36544862-A3310C93-0876-42F6-9F7B-398B13B32591Q36677456-069D2A03-0484-4593-810F-42C9962BE3C5Q36822880-4AB49DED-ADD2-4532-9ECA-12AF334D7F6BQ36977823-243E6173-BA70-4F84-A8CD-3D38FE0A960CQ36997505-B112394F-F320-4C1C-B6F8-721394258876Q37112773-3BB6E532-5F46-4206-A295-8044DD890F31Q37141914-55A7A5BA-1E92-4A39-B408-5807FC6F4818Q37169157-EC8A4966-7E57-4BFD-8F0B-EF629C983569Q37183434-BF263496-6E5B-40E2-8F9F-F457E7E4260CQ37376981-552C4139-6BD7-4D18-860E-17D009A6D897Q37429070-317E24C0-C93C-4D0D-A1EE-904C874C6538Q37523302-713EEB73-3E41-460E-B762-558AC4F2E628Q37598769-82E9DFD3-E659-4463-BC3B-44E4DAEF7BFBQ37740931-3489B8E0-A9BF-4F73-9C34-177160D0C541Q37810110-DEDE26D9-B570-4B68-A1CE-B5446BED2AC1Q37966915-8239F55D-3418-491C-85D2-B4CFBB3AC1B0Q38265086-601822CC-C28C-412F-B224-DED6AB3BB15DQ38640422-E54216DB-E844-4046-8867-7D2C52B18A22Q38729630-A747606B-800E-48C2-8859-627471959EA2Q38772165-39DEF57B-6575-444C-9568-2C7B44767592Q38879793-9C9222BD-EB34-4B61-8B00-894CAB29881EQ38960724-C58B655C-66B0-4951-8DF9-CEC9C31FAEAF
P2860
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Inhibition of the ABL kinase a ...... c cells and induces apoptosis.
@en
type
label
Inhibition of the ABL kinase a ...... c cells and induces apoptosis.
@en
prefLabel
Inhibition of the ABL kinase a ...... c cells and induces apoptosis.
@en
P2093
P356
P1476
Inhibition of the ABL kinase a ...... ic cells and induces apoptosis
@en
P2093
Bertazzoli C
Marchesi E
Pogliani E
le Coutre P
P304
P356
10.1006/BCMD.1997.0155
P577
1997-12-01T00:00:00Z